Adult human mesenchymal stromal cells and the treatment of graft versus host disease

Graft versus host disease is a difficult and potentially lethal complication of hematopoietic stem cell transplantation. It occurs with minor human leucocyte antigen (HLA) mismatch and is normally treated with corticosteroid and other immunosuppressive therapy. When it is refractory to steroid thera...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells and cloning 2014-01, Vol.7 (default), p.45-52
Main Authors: Herrmann, Richard P, Sturm, Marian J
Format: Article
Language:English
Subjects:
Analysis
Biomarkers
Biopsy
Blood transfusion
Bone marrow
Bone marrow transplantation
Care and treatment
Clinical trials
Corticosteroids
Graft vs. host disease
Health aspects
Immune system
Leukemia
Liver
Mesenchymal stem cells
Patients
Review
Risk factors
Stem cells
Transplants & implants
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c576t-2d69c2e8ccd2ff83da506a85b90318b35a2f019b506aa6162734a2d908b2ca933
cites
container_end_page 52
container_issue default
container_start_page 45
container_title Stem cells and cloning
container_volume 7
creator Herrmann, Richard P
Sturm, Marian J
description Graft versus host disease is a difficult and potentially lethal complication of hematopoietic stem cell transplantation. It occurs with minor human leucocyte antigen (HLA) mismatch and is normally treated with corticosteroid and other immunosuppressive therapy. When it is refractory to steroid therapy, mortality approaches 80%. Mesenchymal stromal cells are rare cells found in bone marrow and other tissues. They can be expanded in culture and possess complex and diverse immunomodulatory activity. Moreover, human mesenchymal stromal cells carry low levels of class 1 and no class 2 HLA antigens, making them immunoprivileged and able to be used without HLA matching. Their use in steroid-refractory graft versus host disease was first described in 2004. Subsequently, they have been used in a number of Phase I and II trials in acute and chronic graft versus host disease trials with success. We discuss their mode of action, the results, their production, and potential dangers with a view to future application.
doi_str_mv 10.2147/SCCAA.S37506
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8009406fc0f44d53917fb549c9e75609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A412982344</galeid><doaj_id>oai_doaj_org_article_8009406fc0f44d53917fb549c9e75609</doaj_id><sourcerecordid>A412982344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-2d69c2e8ccd2ff83da506a85b90318b35a2f019b506aa6162734a2d908b2ca933</originalsourceid><addsrcrecordid>eNptkstr3DAQxk1paUKaW89FUCg9dLd6WtalsCx9BAI9JD2LsR5rL7aVSnIg_33lbBp2S6WDxOg3nzSfpqreErymhMvPN9vtZrO-YVLg-kV1TohsVrUS8uXR_qy6TGmPy2CKKklfV2eU11TWnJ9Xtxs7Dxl18wgTGl1yk-keRhhQyjEsq3HDkBBMFuXOoRwd5NFNGQWPdhF8RvcupjmhLqSMbJ8cJPemeuVhSO7yab2ofn37erv9sbr--f1qu7leGSHrvKK2Voa6xhhLvW-YhVIFNKJVmJGmZQKox0S1SxRqUp7MOFCrcNNSA4qxi-rqoGsD7PVd7EeIDzpArx8DIe40xNybwekGY8Vx7Q32nFvBFJG-FVwZ5aSosSpaXw5ad3M7OmtKjRGGE9HTk6nv9C7ca6a4wFwWgY9PAjH8nl3KeuzT4h5MLsxJE8Fx-ROBSUHf_4PuwxynYpWmlDY1p1gdUTsoBfSTD-Ves4jqDSdUNZRxXqj1f6gyrRt7Eybn-xI_SfhwlNA5GHKXwjDnPkzpFPx0AE0MKUXnn80gWC_dpx-7Tx-6r-Dvjg18hv_2GvsD7a3Row</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2228642091</pqid></control><display><type>article</type><title>Adult human mesenchymal stromal cells and the treatment of graft versus host disease</title><source>Publicly Available Content Database</source><source>PubMed</source><source>IngentaConnect Journals</source><source>Taylor &amp; Francis (Open access)</source><creator>Herrmann, Richard P ; Sturm, Marian J</creator><creatorcontrib>Herrmann, Richard P ; Sturm, Marian J</creatorcontrib><description>Graft versus host disease is a difficult and potentially lethal complication of hematopoietic stem cell transplantation. It occurs with minor human leucocyte antigen (HLA) mismatch and is normally treated with corticosteroid and other immunosuppressive therapy. When it is refractory to steroid therapy, mortality approaches 80%. Mesenchymal stromal cells are rare cells found in bone marrow and other tissues. They can be expanded in culture and possess complex and diverse immunomodulatory activity. Moreover, human mesenchymal stromal cells carry low levels of class 1 and no class 2 HLA antigens, making them immunoprivileged and able to be used without HLA matching. Their use in steroid-refractory graft versus host disease was first described in 2004. Subsequently, they have been used in a number of Phase I and II trials in acute and chronic graft versus host disease trials with success. We discuss their mode of action, the results, their production, and potential dangers with a view to future application.</description><identifier>ISSN: 1178-6957</identifier><identifier>EISSN: 1178-6957</identifier><identifier>DOI: 10.2147/SCCAA.S37506</identifier><identifier>PMID: 24627644</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Biomarkers ; Biopsy ; Blood transfusion ; Bone marrow ; Bone marrow transplantation ; Care and treatment ; Clinical trials ; Corticosteroids ; Graft vs. host disease ; Health aspects ; Immune system ; Leukemia ; Liver ; Mesenchymal stem cells ; Patients ; Review ; Risk factors ; Stem cells ; Transplants &amp; implants</subject><ispartof>Stem cells and cloning, 2014-01, Vol.7 (default), p.45-52</ispartof><rights>COPYRIGHT 2014 Dove Medical Press Limited</rights><rights>2014. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Herrmann and Sturm. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-2d69c2e8ccd2ff83da506a85b90318b35a2f019b506aa6162734a2d908b2ca933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2228642091/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2228642091?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24627644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herrmann, Richard P</creatorcontrib><creatorcontrib>Sturm, Marian J</creatorcontrib><title>Adult human mesenchymal stromal cells and the treatment of graft versus host disease</title><title>Stem cells and cloning</title><addtitle>Stem Cells Cloning</addtitle><description>Graft versus host disease is a difficult and potentially lethal complication of hematopoietic stem cell transplantation. It occurs with minor human leucocyte antigen (HLA) mismatch and is normally treated with corticosteroid and other immunosuppressive therapy. When it is refractory to steroid therapy, mortality approaches 80%. Mesenchymal stromal cells are rare cells found in bone marrow and other tissues. They can be expanded in culture and possess complex and diverse immunomodulatory activity. Moreover, human mesenchymal stromal cells carry low levels of class 1 and no class 2 HLA antigens, making them immunoprivileged and able to be used without HLA matching. Their use in steroid-refractory graft versus host disease was first described in 2004. Subsequently, they have been used in a number of Phase I and II trials in acute and chronic graft versus host disease trials with success. We discuss their mode of action, the results, their production, and potential dangers with a view to future application.</description><subject>Analysis</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Blood transfusion</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Corticosteroids</subject><subject>Graft vs. host disease</subject><subject>Health aspects</subject><subject>Immune system</subject><subject>Leukemia</subject><subject>Liver</subject><subject>Mesenchymal stem cells</subject><subject>Patients</subject><subject>Review</subject><subject>Risk factors</subject><subject>Stem cells</subject><subject>Transplants &amp; implants</subject><issn>1178-6957</issn><issn>1178-6957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkstr3DAQxk1paUKaW89FUCg9dLd6WtalsCx9BAI9JD2LsR5rL7aVSnIg_33lbBp2S6WDxOg3nzSfpqreErymhMvPN9vtZrO-YVLg-kV1TohsVrUS8uXR_qy6TGmPy2CKKklfV2eU11TWnJ9Xtxs7Dxl18wgTGl1yk-keRhhQyjEsq3HDkBBMFuXOoRwd5NFNGQWPdhF8RvcupjmhLqSMbJ8cJPemeuVhSO7yab2ofn37erv9sbr--f1qu7leGSHrvKK2Voa6xhhLvW-YhVIFNKJVmJGmZQKox0S1SxRqUp7MOFCrcNNSA4qxi-rqoGsD7PVd7EeIDzpArx8DIe40xNybwekGY8Vx7Q32nFvBFJG-FVwZ5aSosSpaXw5ad3M7OmtKjRGGE9HTk6nv9C7ca6a4wFwWgY9PAjH8nl3KeuzT4h5MLsxJE8Fx-ROBSUHf_4PuwxynYpWmlDY1p1gdUTsoBfSTD-Ves4jqDSdUNZRxXqj1f6gyrRt7Eybn-xI_SfhwlNA5GHKXwjDnPkzpFPx0AE0MKUXnn80gWC_dpx-7Tx-6r-Dvjg18hv_2GvsD7a3Row</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Herrmann, Richard P</creator><creator>Sturm, Marian J</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140101</creationdate><title>Adult human mesenchymal stromal cells and the treatment of graft versus host disease</title><author>Herrmann, Richard P ; Sturm, Marian J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-2d69c2e8ccd2ff83da506a85b90318b35a2f019b506aa6162734a2d908b2ca933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Blood transfusion</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Corticosteroids</topic><topic>Graft vs. host disease</topic><topic>Health aspects</topic><topic>Immune system</topic><topic>Leukemia</topic><topic>Liver</topic><topic>Mesenchymal stem cells</topic><topic>Patients</topic><topic>Review</topic><topic>Risk factors</topic><topic>Stem cells</topic><topic>Transplants &amp; implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herrmann, Richard P</creatorcontrib><creatorcontrib>Sturm, Marian J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Stem cells and cloning</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herrmann, Richard P</au><au>Sturm, Marian J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adult human mesenchymal stromal cells and the treatment of graft versus host disease</atitle><jtitle>Stem cells and cloning</jtitle><addtitle>Stem Cells Cloning</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>7</volume><issue>default</issue><spage>45</spage><epage>52</epage><pages>45-52</pages><issn>1178-6957</issn><eissn>1178-6957</eissn><abstract>Graft versus host disease is a difficult and potentially lethal complication of hematopoietic stem cell transplantation. It occurs with minor human leucocyte antigen (HLA) mismatch and is normally treated with corticosteroid and other immunosuppressive therapy. When it is refractory to steroid therapy, mortality approaches 80%. Mesenchymal stromal cells are rare cells found in bone marrow and other tissues. They can be expanded in culture and possess complex and diverse immunomodulatory activity. Moreover, human mesenchymal stromal cells carry low levels of class 1 and no class 2 HLA antigens, making them immunoprivileged and able to be used without HLA matching. Their use in steroid-refractory graft versus host disease was first described in 2004. Subsequently, they have been used in a number of Phase I and II trials in acute and chronic graft versus host disease trials with success. We discuss their mode of action, the results, their production, and potential dangers with a view to future application.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>24627644</pmid><doi>10.2147/SCCAA.S37506</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6957
ispartof Stem cells and cloning, 2014-01, Vol.7 (default), p.45-52
issn 1178-6957
1178-6957
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8009406fc0f44d53917fb549c9e75609
source Publicly Available Content Database; PubMed; IngentaConnect Journals; Taylor & Francis (Open access)
subjects Analysis
Biomarkers
Biopsy
Blood transfusion
Bone marrow
Bone marrow transplantation
Care and treatment
Clinical trials
Corticosteroids
Graft vs. host disease
Health aspects
Immune system
Leukemia
Liver
Mesenchymal stem cells
Patients
Review
Risk factors
Stem cells
Transplants & implants
title Adult human mesenchymal stromal cells and the treatment of graft versus host disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A08%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adult%20human%20mesenchymal%20stromal%20cells%20and%20the%20treatment%20of%20graft%20versus%20host%20disease&rft.jtitle=Stem%20cells%20and%20cloning&rft.au=Herrmann,%20Richard%20P&rft.date=2014-01-01&rft.volume=7&rft.issue=default&rft.spage=45&rft.epage=52&rft.pages=45-52&rft.issn=1178-6957&rft.eissn=1178-6957&rft_id=info:doi/10.2147/SCCAA.S37506&rft_dat=%3Cgale_doaj_%3EA412982344%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c576t-2d69c2e8ccd2ff83da506a85b90318b35a2f019b506aa6162734a2d908b2ca933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2228642091&rft_id=info:pmid/24627644&rft_galeid=A412982344&rfr_iscdi=true